REFERENCES
- Krymchantowski AV, Bigal ME, Moreira PF, New and emerging prophylactic agents for migraine, CNS Drugs 16, 611–34 (2002).
- Okada M, Kaneko S, Hirano T, et al., Effects of zonisamide on dopaminergic system, Epilepsy Res 22, 193–205 (1995).
- Okada M, Hirano T, Kawata Y, et al., Biphasic effects of zonisamide on serotonergic system in rat hippocampus, Epilepsy Res 34, 187–97 (1999).
- Zhu W, Rogawski A, Zonisamide depresses excitatory synaptic transmission by a presynaptic action [abstract], Epilepsia 40, 245 (1999).
- Okada M, Kawata Y, Mizuno K, et al., Interaction between Ca2+, K+, carbamazepine and zonisamide on hippocamp al extracellular glutamate monitored with a microdialysis electrode, Br J Phannacol 124, 1277–85 (1998).
- Endoh A, Kinno E, Kawai M, et al., Effect of zonisamide on neurotransmitter in mouse brain, Neurosciences 20, P173–6 (1994).
- Kawai M, Endo A, Kinno I, et al., Effect of zonisamide on release of aspartic acid and gamma-aminobutyric acid from the hippocampal slices of El mice, Neurosciences 20, 115–9 (1994).
- Cochran JW, Open-label experience in patients with migraine and facial pain: efficacy of zonisamide as prophylaxis [abstract], Headache 42, 434 (2002).
- Krusz JC, Zonisamide in the treatment of headache disorders [abstract], Headache 42, 459 (2002).
- Drake ME Jr, Greathouse NI, Armentbright AD, et al., Zonis amide in the prophylaxis of migraine headache [abstract], J Pain 3 ( 2 suppl. 1), 39 (2002).